CA2417258A1 - Systeme d'aromatisation pour compositions pharmaceutiques et procedes de fabrication de telles compositions - Google Patents

Systeme d'aromatisation pour compositions pharmaceutiques et procedes de fabrication de telles compositions Download PDF

Info

Publication number
CA2417258A1
CA2417258A1 CA002417258A CA2417258A CA2417258A1 CA 2417258 A1 CA2417258 A1 CA 2417258A1 CA 002417258 A CA002417258 A CA 002417258A CA 2417258 A CA2417258 A CA 2417258A CA 2417258 A1 CA2417258 A1 CA 2417258A1
Authority
CA
Canada
Prior art keywords
flavored
weight
pharmaceutical composition
mixtures
ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002417258A
Other languages
English (en)
Inventor
Laman Alani
Donald P. Gauwitz
Dilip Kaul
John M. Lipari
Soumojeet Ghosh
Kennan C. Marsh
Richard H. Whelan
Vanik D. Petrossian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2417258A1 publication Critical patent/CA2417258A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fats And Perfumes (AREA)

Abstract

L'invention concerne un système d'aromatisation pour une composition pharmaceutique liquides, ainsi que des compositions pharmaceutiques contenant de tels systèmes d'aromatisation. Les systèmes d'aromatisation de cette invention comprennent au moins un édulcorant, au moins deux ingrédients aromatisés, et au moins un modificateur d'arôme choisi dans le groupe comprenant acide citrique, citrate de sodium, chlorure de sodium et des mélanges de ceux-ci. Au moins deux des ingrédients aromatisés sont choisis dans le groupe comprenant un ingrédient aromatisé à la vanille, un ingrédient aromatisé à la menthe poivrée, un ingrédient aromatisé au menthol, un ingrédient aromatisé à la barbe à papa, et des mélanges de ceux-ci. Le ou les édulcorants comprennent de la glycérine, du glycyrrhizinate monoammonique, du sodium de saccharine, de l'acésulfame-potassium, du sirop de glucose à haute teneur en fructose, et/ou des mélanges de ceux-ci. Les compositions pharmaceutiques de cette invention comprennent un système d'aromatisation de l'invention, un système de solvant, et au moins un agent actif du point de vue pharmaceutique, tel que du lopinavir ou des dérivés de celui-ci, du ritonavir ou des dérivés de celui-ci, ou des mélanges de ceux-ci. L'invention concerne également des procédés de fabrication de telles compositions pharmaceutiques liquides.
CA002417258A 2000-09-05 2001-09-04 Systeme d'aromatisation pour compositions pharmaceutiques et procedes de fabrication de telles compositions Abandoned CA2417258A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65519200A 2000-09-05 2000-09-05
US09/655,192 2000-09-05
PCT/US2001/027415 WO2002020057A2 (fr) 2000-09-05 2001-09-04 Systeme d'aromatisation pour compositions pharmaceutiques et procedes de fabrication de telles compositions

Publications (1)

Publication Number Publication Date
CA2417258A1 true CA2417258A1 (fr) 2002-03-14

Family

ID=24627898

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002417258A Abandoned CA2417258A1 (fr) 2000-09-05 2001-09-04 Systeme d'aromatisation pour compositions pharmaceutiques et procedes de fabrication de telles compositions

Country Status (10)

Country Link
EP (1) EP1315487A2 (fr)
JP (1) JP2004522698A (fr)
AR (1) AR030715A1 (fr)
AU (1) AU2001288695A1 (fr)
BR (1) BR0108433A (fr)
CA (1) CA2417258A1 (fr)
MX (1) MXPA03001952A (fr)
PE (1) PE20020373A1 (fr)
UY (1) UY26925A1 (fr)
WO (1) WO2002020057A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1175205B1 (fr) 1999-11-12 2006-06-14 Abbott Laboratories Dispersion solide comrpenant ritonavir, fenofibrate ou griseofulvin
BR0316318A (pt) * 2002-11-22 2005-09-27 Firmenich & Cie Composição oral, e, método de mascarar o gosto salgado de um sal em uma composição oral
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
GB2423711B (en) * 2005-10-24 2007-02-14 Fortune Apex Dev Ltd Method for preparing a pharmaceutical composition with enhanced mucoadhesion
TW201340998A (zh) * 2012-02-29 2013-10-16 Takeda Pharmaceutical 經口劑
US8771651B2 (en) * 2012-09-10 2014-07-08 Johnson & Johnson Consumer Companies, Inc. Mouth rinses and tooth sensitivity treatment compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111991A (en) * 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
AU3146997A (en) * 1996-06-03 1998-01-05 Merck & Co., Inc. Pediatric formulation for hiv protease inhibitors

Also Published As

Publication number Publication date
EP1315487A2 (fr) 2003-06-04
UY26925A1 (es) 2002-04-26
AR030715A1 (es) 2003-09-03
MXPA03001952A (es) 2003-09-10
PE20020373A1 (es) 2002-05-13
JP2004522698A (ja) 2004-07-29
WO2002020057A2 (fr) 2002-03-14
WO2002020057A3 (fr) 2002-05-10
BR0108433A (pt) 2006-06-06
AU2001288695A1 (en) 2002-03-22

Similar Documents

Publication Publication Date Title
US8895051B2 (en) Flavoring systems for pharmaceutical compositions and methods of making such compositions
US6806256B2 (en) Taste masked liquid pharmaceutical compositions
US5024997A (en) Palatable ibuprofen solutions
AU2002257104A1 (en) Antifungal composition with enhanced bioavailability
NZ229698A (en) Effervescent composition comprised of ranitidine, a mono alkali metal citrate and an alkaline carbonate or bicarbonate
KR101490721B1 (ko) 감칠맛을 가진 디페리프론용 액상 제제
EP1543831A1 (fr) Composition de pregabaline
WO2006018814A2 (fr) Suspensions liquides orales de métaxalone
RU2363462C2 (ru) Фармацевтическая композиция, содержащая 5-метил-2-(2′-хлор-6′-фторанилин)фенилуксусную кислоту
CA2417258A1 (fr) Systeme d'aromatisation pour compositions pharmaceutiques et procedes de fabrication de telles compositions
KR100900064B1 (ko) 의약 액제
WO2009112800A1 (fr) Composition de losartan
KR20050034619A (ko) 신규한 무수 및 수성 에피나스틴 시럽 제형
KR102556874B1 (ko) 비스포스포네이트 및 콜레칼시페롤을 함유하는 경구용 에멀젼 조성물 및 그 제조방법
US20060100271A1 (en) Stabilized aqueous ranitidine compositions
US6265449B1 (en) Aqueous compositions comprising ranitidine and LCMT sucrose
US20040039036A1 (en) Water-soluble liquid internal medicine
JP2003095933A (ja) 内服液剤組成物
KR0169402B1 (ko) 티아졸리딘 2,4-디카르복실산 아르기닌염(아르기닌티디아시케이트)함유액제 및 그의 제조방법
UA112905C2 (uk) Педіатрична рідка композиція для перорального введення, що містить непадутант
US20230082870A1 (en) Composition for calcium supplementation
JP2008088116A (ja) 水性内服液剤組成物
US20200375897A1 (en) Composition for calcium supplementation
WO2017077425A1 (fr) Solution orale à base d'inhibiteurs d'ace
JPH10203971A (ja) 水性経口液剤

Legal Events

Date Code Title Description
FZDE Dead